Prothena to Report Second Quarter 2024 Financial Results on August 8
Prothena plc (NASDAQ:PRTA), a late-stage clinical biotechnology company specializing in protein dysregulation, has announced it will release its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024, after the U.S. financial markets close. The company, which focuses on developing investigational therapeutics, has stated that it will not conduct a conference call in conjunction with this financial results release, maintaining its usual practice.
Prothena plc (NASDAQ:PRTA), un azienda biotecnologica clinica in fase avanzata specializzata nella disfunzione proteica, ha annunciato che pubblicherà i risultati finanziari del secondo trimestre e dei primi sei mesi del 2024 giovedì 8 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda, che si concentra sullo sviluppo di terapie sperimentali, ha dichiarato che non svolgerà una conferenza telefonica in concomitanza con questa pubblicazione dei risultati finanziari, mantenendo la consueta prassi.
Prothena plc (NASDAQ:PRTA), una empresa biotecnológica clínica de última etapa especializada en la disregulación proteica, ha anunciado que publicará sus resultados financieros del segundo trimestre y de los primeros seis meses de 2024 el jueves 8 de agosto de 2024, después del cierre de los mercados financieros de EE. UU. La empresa, que se centra en desarrollar terapias en investigación, ha declarado que no realizará una llamada de conferencia junto con esta publicación de resultados financieros, manteniendo su práctica habitual.
프로시나 plc (NASDAQ:PRTA)는 단백질 비정상화 전문의 후기 단계 임상 생명공학 회사로, 2024년 2분기 및 첫 6개월 재무 결과를 2024년 8월 8일 목요일, 미국 금융 시장 폐장 후 발표할 것이라고 밝혔습니다. 연구 치료제를 개발하는 데 중점을 두고 있는 회사는 이번 재무 결과 발표에 컨퍼런스 콜을 진행하지 않을 것이며, 이는 그들의 일반적인 관행을 유지하는 것이라고 전했습니다.
Prothena plc (NASDAQ:PRTA), une entreprise de biotechnologie clinique en phase avancée spécialisée dans la dysrégulation des protéines, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre et les six premiers mois de 2024 le jeudi 8 août 2024, après la fermeture des marchés financiers américains. L'entreprise, qui se concentre sur le développement de thérapeutiques expérimentales, a déclaré qu'elle ne tiendrait pas de conférence téléphonique en lien avec cette publication des résultats financiers, maintenant ainsi sa pratique habituelle.
Prothena plc (NASDAQ:PRTA), ein biotechnologisches Unternehmen in der späten klinischen Phase, das sich auf Protein-Dysregulation spezialisiert hat, gab bekannt, dass es am Donnerstag, den 8. August 2024, nach dem Schließen der US-Finanzmärkte seine Finanzzahlen für das zweite Quartal und die ersten sechs Monate des Jahres 2024 veröffentlichen wird. Das Unternehmen, das sich auf die Entwicklung von experimentellen Therapeutika konzentriert, hat erklärt, dass es keine Telefonkonferenz in Zusammenhang mit dieser Veröffentlichung der Finanzzahlen abhalten wird, was der üblichen Praxis entspricht.
- None.
- None.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801426590/en/
Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Source: Prothena Corporation plc
FAQ
When will Prothena (PRTA) release its Q2 2024 financial results?
Will Prothena (PRTA) hold a conference call for its Q2 2024 earnings release?
What is Prothena's (PRTA) primary focus as a biotechnology company?
